MA52560A - Composés hétéroaryles tétracycliques - Google Patents
Composés hétéroaryles tétracycliquesInfo
- Publication number
- MA52560A MA52560A MA052560A MA52560A MA52560A MA 52560 A MA52560 A MA 52560A MA 052560 A MA052560 A MA 052560A MA 52560 A MA52560 A MA 52560A MA 52560 A MA52560 A MA 52560A
- Authority
- MA
- Morocco
- Prior art keywords
- heteraryl
- tetracyclic
- compounds
- tetracyclic heteraryl
- heteraryl compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668321P | 2018-05-08 | 2018-05-08 | |
| US201862754814P | 2018-11-02 | 2018-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52560A true MA52560A (fr) | 2021-03-17 |
Family
ID=66484036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052560A MA52560A (fr) | 2018-05-08 | 2019-05-07 | Composés hétéroaryles tétracycliques |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11407765B2 (fr) |
| EP (1) | EP3790884A1 (fr) |
| JP (1) | JP7138724B2 (fr) |
| KR (1) | KR20210006948A (fr) |
| CN (1) | CN112074520A (fr) |
| AU (1) | AU2019267008B2 (fr) |
| BR (1) | BR112020021467A2 (fr) |
| CA (1) | CA3098261A1 (fr) |
| CL (1) | CL2020002866A1 (fr) |
| CO (1) | CO2020013564A2 (fr) |
| CR (1) | CR20200532A (fr) |
| DO (1) | DOP2020000201A (fr) |
| EC (1) | ECSP20070854A (fr) |
| JO (1) | JOP20200281A1 (fr) |
| MA (1) | MA52560A (fr) |
| MX (1) | MX2020011910A (fr) |
| NI (1) | NI202000078A (fr) |
| PE (1) | PE20211795A1 (fr) |
| PH (1) | PH12020551870A1 (fr) |
| SG (1) | SG11202010953QA (fr) |
| TW (1) | TW202012415A (fr) |
| UY (1) | UY38221A (fr) |
| WO (1) | WO2019215203A1 (fr) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3792260T3 (pl) | 2018-05-08 | 2024-12-02 | Nippon Shinyaku Co., Ltd. | Związki azabenzimidazolowe i środki farmaceutyczne |
| JP7451419B2 (ja) | 2018-10-26 | 2024-03-18 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| CR20210504A (es) * | 2019-03-05 | 2022-02-08 | Astrazeneca Ab | Compuestos tricíclicos condensados útiles como agentes anticancerígenos |
| US20220251109A1 (en) * | 2019-04-28 | 2022-08-11 | Genfleet Therapeutics (Shanghai) Inc. | Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof |
| CR20220230A (es) | 2019-10-28 | 2022-06-15 | Merck Sharp & Dohme | Inhibidores de pequeñas moléculas de mutante g12c de kras |
| EP4054719B1 (fr) | 2019-11-04 | 2026-02-11 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| KR20220109407A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| JP7823816B2 (ja) | 2019-11-04 | 2026-03-04 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｒａｓ阻害剤 |
| WO2021095801A1 (fr) | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | Composé azabenzimidazole et médicament |
| WO2021108683A1 (fr) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| EP4067343A4 (fr) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Nouveau composé phénolique ou sel de celui-ci |
| UA128806C2 (uk) * | 2019-12-11 | 2024-10-23 | Елі Ліллі Енд Компані | Інгібітори kras g12c |
| WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
| PY2125608A (es) * | 2020-04-01 | 2021-12-28 | Fmc Corp | Atropisómeros de derivados de piridazinona como herbicidas |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| CA3183032A1 (fr) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methodes de retardement, de prevention et de traitement de la resistance acquise aux inhibiteurs de ras |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| TWI829003B (zh) | 2020-08-12 | 2024-01-11 | 美商建南德克公司 | 喹唑啉化合物之合成 |
| EP4203952A4 (fr) | 2020-08-28 | 2024-12-11 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| US12162893B2 (en) | 2020-09-23 | 2024-12-10 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133345A1 (fr) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Pyridones et pyrimidones tricycliques |
| CN114685531B (zh) * | 2020-12-25 | 2024-10-22 | 武汉誉祥医药科技有限公司 | 四并环化合物及其药物组合物和应用 |
| TWI824405B (zh) * | 2021-02-09 | 2023-12-01 | 美商建南德克公司 | 四環氧氮呯化合物及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| US20240174691A1 (en) * | 2021-03-17 | 2024-05-30 | Genfleet Therapeutics (Shanghai) Inc. | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| WO2022199587A1 (fr) * | 2021-03-24 | 2022-09-29 | 南京明德新药研发有限公司 | Composé hétérocyclique de pyrimidine et son application |
| CN116113632B (zh) * | 2021-03-30 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| AU2022254674A1 (en) * | 2021-04-08 | 2023-10-12 | Genentech, Inc. | Oxazepine compounds and uses thereof in the treatment of cancer |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| BR112023024646A2 (pt) * | 2021-06-21 | 2024-03-05 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina |
| CA3224284A1 (fr) * | 2021-07-02 | 2023-01-05 | Feng Wang | Inhibiteur de kras g12d et son utilisation |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| CA3226720A1 (fr) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Inhibiteurs de kras g12d et leurs utilisations |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202327569A (zh) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 |
| EP4389751A1 (fr) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| KR20240070619A (ko) * | 2021-09-27 | 2024-05-21 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | 폴리사이클릭 융합 고리 유도체 및 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| AU2022371727A1 (en) | 2021-10-22 | 2024-05-02 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| TW202325298A (zh) * | 2021-11-01 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮的四環化合物、其製備方法及其在醫藥上的應用 |
| WO2023103906A1 (fr) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Inhibiteur ciblant la kras g12d et son utilisation en médecine |
| JP2025500878A (ja) | 2021-12-17 | 2025-01-15 | ジェンザイム・コーポレーション | Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物 |
| EP4456899A1 (fr) | 2021-12-28 | 2024-11-06 | AstraZeneca UK Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de rasg12c |
| EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| JP2025508133A (ja) | 2022-03-11 | 2025-03-21 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| AU2023272945A1 (en) | 2022-05-19 | 2024-11-07 | Genentech, Inc. | Aza-tetracyclic oxazepine compounds and uses thereof |
| WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
| WO2024031088A1 (fr) * | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| CN119654327A (zh) * | 2022-08-11 | 2025-03-18 | 百济神州(苏州)生物科技有限公司 | 杂环化合物、其组合物及其治疗方法 |
| CN119768409A (zh) * | 2022-08-25 | 2025-04-04 | 北京加科思新药研发有限公司 | K-Ras突变蛋白抑制剂 |
| WO2024138486A1 (fr) * | 2022-12-29 | 2024-07-04 | Nikang Therapeutics, Inc. | Dérivés tétracycliques en tant qu'inhibiteurs de kras |
| JP2025532125A (ja) * | 2022-09-23 | 2025-09-29 | アイディーエンス カンパニー リミテッド | 新規なテトラヘテロサイクル化合物 |
| WO2024063576A1 (fr) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Nouveau composé de quinazoline en tant qu'inhibiteur de kras |
| JP2025535294A (ja) * | 2022-10-18 | 2025-10-24 | アイディーエンス カンパニー リミテッド | 新規なトリヘテロ環化合物 |
| AU2023377064A1 (en) | 2022-11-09 | 2025-05-22 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024120419A1 (fr) * | 2022-12-06 | 2024-06-13 | Zai Lab (Shanghai) Co., Ltd. | Composés tétracycliques fusionnés en tant que modulateurs de kras g12d et leurs utilisations |
| CN120322441A (zh) * | 2022-12-20 | 2025-07-15 | 江苏恒瑞医药股份有限公司 | 一种kras g12d抑制剂的结晶形式及制备方法 |
| WO2024149214A1 (fr) * | 2023-01-10 | 2024-07-18 | Nikang Therapeutics, Inc. | Composés bifonctionnels pour dégrader kras-12d par l'intermédiaire de la voie ubiquitine-protéasome |
| WO2024153119A1 (fr) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Inhibiteurs de kras g12d et leurs utilisations |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| PE20260039A1 (es) | 2023-04-07 | 2026-01-09 | Revolution Medicines Inc | Inhibidores macrociclicos de ras |
| WO2024211663A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| TW202506128A (zh) | 2023-04-14 | 2025-02-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之ｋｒａｓ抑制劑及ａｔｒ抑制劑之組合 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202442647A (zh) * | 2023-04-21 | 2024-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種含氮四環化合物的結晶形式及其製備方法 |
| WO2024229406A1 (fr) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Polythérapie pour une maladie ou un trouble lié à ras |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| KR20260020406A (ko) | 2023-06-02 | 2026-02-11 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트와 rasg12c 저해제의 조합 |
| WO2025007000A1 (fr) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Composés aminés tricycliques condensés substitués et leurs utilisations en tant qu'inhibiteurs de ras |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| TW202523291A (zh) * | 2023-11-02 | 2025-06-16 | 美商金橘生物科技公司 | 降解劑及其用途 |
| TW202545999A (zh) | 2024-02-06 | 2025-12-01 | 美商金橘生物科技公司 | 雜環綴合物及其用途 |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025230971A1 (fr) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques en tant qu'agents anticancéreux |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| EP2970121B1 (fr) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Inhibiteurs covalents de k-ras g12c |
| WO2014143659A1 (fr) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Inhibiteurs covalents irréversibles de la gtpase k-ras g12c |
| EP3636639A1 (fr) * | 2013-10-10 | 2020-04-15 | Araxes Pharma LLC | Inhibiteurs de kras g12c |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| CA2993013A1 (fr) | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Composes de quinazoline substitues et leur utilisation en tant qu'inhibiteurs de proteines kras, hras et/ou nras mutantes g12c |
| WO2017058792A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356347A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356353A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| SG11201810171SA (en) | 2016-05-18 | 2018-12-28 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| WO2018064510A1 (fr) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| NZ754994A (en) | 2016-12-22 | 2022-12-23 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| WO2018140600A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation |
| JP2020505395A (ja) | 2017-01-26 | 2020-02-20 | アラクセス ファーマ エルエルシー | 縮合ｎ−複素環式化合物およびその使用方法 |
| EP3573971A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
| EP3573954A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140599A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| WO2018206539A1 (fr) | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Composés hétéroaryle inhibant des protéines ras portant la mutation g12c |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| WO2018218069A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| PT3710439T (pt) | 2017-11-15 | 2023-05-15 | Array Biopharma Inc | Inibidores de kras g12c |
| WO2019110751A1 (fr) | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Composés tétracycliques en tant qu'inhibiteurs de la protéine ras mutante g12c, destinés à être utilisés en tant qu'agents anticancéreux |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
-
2019
- 2019-05-03 TW TW108115329A patent/TW202012415A/zh unknown
- 2019-05-07 US US17/053,400 patent/US11407765B2/en active Active
- 2019-05-07 PE PE2020001766A patent/PE20211795A1/es unknown
- 2019-05-07 AU AU2019267008A patent/AU2019267008B2/en not_active Expired - Fee Related
- 2019-05-07 JP JP2020560800A patent/JP7138724B2/ja active Active
- 2019-05-07 CA CA3098261A patent/CA3098261A1/fr active Pending
- 2019-05-07 SG SG11202010953QA patent/SG11202010953QA/en unknown
- 2019-05-07 JO JOP/2020/0281A patent/JOP20200281A1/ar unknown
- 2019-05-07 BR BR112020021467-1A patent/BR112020021467A2/pt not_active Application Discontinuation
- 2019-05-07 EP EP19723368.7A patent/EP3790884A1/fr not_active Withdrawn
- 2019-05-07 KR KR1020207035034A patent/KR20210006948A/ko not_active Withdrawn
- 2019-05-07 CR CR20200532A patent/CR20200532A/es unknown
- 2019-05-07 WO PCT/EP2019/061754 patent/WO2019215203A1/fr not_active Ceased
- 2019-05-07 MX MX2020011910A patent/MX2020011910A/es unknown
- 2019-05-07 MA MA052560A patent/MA52560A/fr unknown
- 2019-05-07 CN CN201980030143.8A patent/CN112074520A/zh active Pending
- 2019-05-08 UY UY38221A patent/UY38221A/es not_active Application Discontinuation
-
2020
- 2020-10-28 CO CONC2020/0013564A patent/CO2020013564A2/es unknown
- 2020-11-04 DO DO2020000201A patent/DOP2020000201A/es unknown
- 2020-11-05 CL CL2020002866A patent/CL2020002866A1/es unknown
- 2020-11-05 PH PH12020551870A patent/PH12020551870A1/en unknown
- 2020-11-06 NI NI202000078A patent/NI202000078A/es unknown
- 2020-11-06 EC ECSENADI202070854A patent/ECSP20070854A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112074520A (zh) | 2020-12-11 |
| DOP2020000201A (es) | 2020-11-30 |
| CO2020013564A2 (es) | 2020-11-10 |
| PE20211795A1 (es) | 2021-09-09 |
| TW202012415A (zh) | 2020-04-01 |
| JP2021532061A (ja) | 2021-11-25 |
| US20210221823A1 (en) | 2021-07-22 |
| CR20200532A (es) | 2020-12-23 |
| KR20210006948A (ko) | 2021-01-19 |
| UY38221A (es) | 2019-10-31 |
| CL2020002866A1 (es) | 2021-02-12 |
| AU2019267008A1 (en) | 2021-01-07 |
| AU2019267008B2 (en) | 2022-02-17 |
| BR112020021467A2 (pt) | 2021-01-19 |
| MX2020011910A (es) | 2021-01-29 |
| US11407765B2 (en) | 2022-08-09 |
| ECSP20070854A (es) | 2020-12-31 |
| EP3790884A1 (fr) | 2021-03-17 |
| PH12020551870A1 (en) | 2021-07-26 |
| JP7138724B2 (ja) | 2022-09-16 |
| WO2019215203A1 (fr) | 2019-11-14 |
| JOP20200281A1 (ar) | 2020-11-05 |
| CA3098261A1 (fr) | 2019-11-14 |
| SG11202010953QA (en) | 2020-12-30 |
| NI202000078A (es) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52560A (fr) | Composés hétéroaryles tétracycliques | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA52948A (fr) | Composés | |
| EP3802467A4 (fr) | Composés spirocycliques | |
| HUE059403T2 (hu) | Vegyületek | |
| EP3781156A4 (fr) | Composés spirocycliques | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| MA51669A (fr) | Composés | |
| EP3956033A4 (fr) | Composés bicycliques | |
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| MA52489A (fr) | Nouveaux composés | |
| MA53003A (fr) | Composés | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| MA44020A (fr) | Composés antitumoraux | |
| EP3853210A4 (fr) | Composés antibactériens | |
| MA50504A (fr) | Composés antibactériens | |
| EP3728289A4 (fr) | Composés optimisés | |
| EP3464336A4 (fr) | Composés | |
| MA52946A (fr) | Composés | |
| EP4077318A4 (fr) | Composés | |
| IL282366A (en) | Tricyclic pesticidal compounds | |
| LT3867247T (lt) | Naujieji junginiai | |
| MA53430A (fr) | Nouveaux composés | |
| EP3717483A4 (fr) | Composés de pyrazolopyridinone | |
| EP3713941A4 (fr) | Composés de pyrazolopyridinone |